HSBC Holdings
AMRX icon

HSBC Holdings’s Amneal Pharmaceuticals AMRX Stock Holding History

HSBC Holdings’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-101,945
Closed -$1.3M – 2888
2025
Q4 		$1.3M Buy
101,945
+1,569
+2% +$18K ﹤0.01% 1796
2025
Q3 		$1.01M Buy
100,376
+33,494
+50% +$301K ﹤0.01% 1790
2025
Q2 		$543K Sell
66,882
-19,830
-23% -$150K ﹤0.01% 2112
2025
Q1 		$727K Buy
86,712
+26,651
+44% +$222K ﹤0.01% 1899
2024
Q4 		$476K Buy
60,061
+13,757
+30% +$115K ﹤0.01% 2212
2024
Q3 		$381K Buy
46,304
+2,463
+6% +$19.3K ﹤0.01% 2169
2024
Q2 		$279K Sell
43,841
-247,568
-85% -$1.57M ﹤0.01% 2335
2024
Q1 		$1.76M Buy
+291,409
New +$1.64M ﹤0.01% 1540
2023
Q4 		– Sell
-11,433
Closed -$47.9K – 2715
2023
Q3 		$47.9K Buy
+11,433
New +$42.6K ﹤0.01% 2634
2023
Q2 		– Sell
-41,979
Closed -$58.9K – 2553
2023
Q1 		$58.9K Hold
41,979
– – ﹤0.01% 2555
2022
Q4 		$83.1K Buy
41,979
+2,536
+6% +$5.68K ﹤0.01% 2929
2022
Q3 		$82K Sell
39,443
-26,460
-40% -$74.2K ﹤0.01% 2770
2022
Q2 		$214K Buy
65,903
+9,735
+17% +$35.3K ﹤0.01% 2847
2022
Q1 		$236K Buy
56,168
+61
+0.1% +$270 ﹤0.01% 2905
2021
Q4 		$272K Buy
+56,107
New +$280K ﹤0.01% 2843
2020
Q3 		– Sell
-18,751
Closed -$89K – 2713
2020
Q2 		$89K Sell
18,751
-1,798
-9% -$7.4K ﹤0.01% 2532
2020
Q1 		$69K Sell
20,549
-52,431
-72% -$222K ﹤0.01% 2518
2019
Q4 		$351K Sell
72,980
-47,794
-40% -$166K ﹤0.01% 2440
2019
Q3 		$350K Buy
+120,774
New +$421K ﹤0.01% 2536
2019
Q2 		– Sell
-31,356
Closed -$445K – 2691
2019
Q1 		$445K Buy
31,356
+5,419
+21% +$71.6K ﹤0.01% 2160
2018
Q4 		$350K Sell
25,937
-2,676
-9% -$48.2K ﹤0.01% 2243
2018
Q3 		$635K Buy
28,613
+3,706
+15% +$78K ﹤0.01% 1921
2018
Q2 		$409K Buy
+24,907
New +$437K ﹤0.01% 2152

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

HSBC Holdings's AMRX Position: Q1 2026 in Review

HSBC Holdings sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 101,945 shares — an estimated $1.3M sold.

HSBC Holdings first reported a position in AMRX in Q2 2018 and held it in 23 quarters. The position peaked at $1.76M in Q1 2024. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • HSBC Holdings reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HSBC Holdings sold 101,945 Amneal Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • HSBC Holdings first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 23 quarters.
  • HSBC Holdings's Amneal Pharmaceuticals position peaked at $1.76M in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.